IINN INSPIRA TECH OXY BHN LTD

Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years

Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years

RA'ANANA, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,“Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has filed a shelf registration statement on Form F-3 (File No. 333-289324) with the U.S. Securities and Exchange Commission on August 6, 2025, as part of a routine shelf renewal process conducted every three years. This updated filing replaces the Company’s previous shelf registration statement, which is set to expire on August 18, 2025.

About Inspira Technologies

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: -technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at .

Company Contact

Inspira Technologies – Media Relations

Email:

Phone:



EN
07/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INSPIRA TECH OXY BHN LTD

 PRESS RELEASE

Inspira Clarifies Routine Nature of Registration Statement on Form F-3...

Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years RA'ANANA, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has filed a shelf registration statement on Form F-3 (File No. 333-289324) with the U.S. Securities and Exchange Commission on August 6, 2025, as part of a routine shelf renewal process conducted every three years. This updated filing repl...

 PRESS RELEASE

Inspira Activates U.S. Based Consulting Firm to Execute Transformation...

Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives RA'ANANA, Israel, July 31, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has activated a leading consulting firm to accelerate high-impact execution across strategic expansion, partner engagement, and advanced structuring pathways already in motion. The consulting firm is a specialized group that partners with biotech and medtech ...

 PRESS RELEASE

Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement

Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement RA'ANANA, Israel, July 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. The notice, dated July 17, 2025, stated that for the 10 consecu...

 PRESS RELEASE

Inspira Achieves All Key Objectives in Previously Announced Government...

Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100 RA'ANANA, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has successfully achieved all key strategic objectives in its high-level talks with a government health authority, located outside of the United States, on July 8, 2025, a meeting previously an...

 PRESS RELEASE

Inspira in High-Level Government Talks to Advance National Integration...

Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework RA'ANANA, Israel, July 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system as a foundational com...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch